23rd Aug 2019 10:59
(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last week.
The study is intended to investigate the safety and efficacy of HMPL-523 as a treatment for immune thrombocytopenia, an autoimmune disorder which can cause increased risk of bleeding.
The condition is associated with fatigue and a reduced quality of life, with symptoms including gastrointestinal and urinary mucosal tract bleeding and bleeding under the skin.
The primary endpoint of the biopharmaceutical company's study is the number of patients who do not experience any adverse events.
Hutchison China is already trialling HMPL-523 in Australia as a treatment for blood cancers.
Shares in Hutchison China were untraded at 334.50 pence in London on Friday.
Related Shares:
Hutchmed